Cbd

Neurotech Demonstrates Potential Benefits for Management of Multiple Sclerosis Disease

Finfeed Archived May 25, 2021

Initial in vitro studies carried out by Neurotech International Limited (ASX: NTI) in collaboration with the internationally recognised Neurodevelopment in Health and Disease Laboratory at RMIT University to assess the effects of the lead NTI/Dolce strains on key neuro-markets that are used in assessing the onset and progression of Multiple Sclerosis (MS).

Revenue generating BDA sets its sights on US market

Finfeed Archived Mar 17, 2021

Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.

Neurotech expands exclusive license to include all neurological disorders

Finfeed Archived Mar 02, 2021

Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.

Neurotech’s key near-term objectives

Finfeed Archived Jan 21, 2021

Neurotech International Limited (ASX: NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered.

NTI Days Away from Crucial Lab Results – Can its Cannabis Strain Treat Autism?

Catalyst Hunter Dec 16, 2020

Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.

$2M in repeat purchase orders display Creso Pharma’s growth potential

Finfeed Archived Oct 13, 2020

Creso Pharma Limited (ASX: CPH, FRA: 1X8) has once again strengthened its revenue profile with another repeat purchase order from South African-based Pharma Dynamics.

How (and why) companies are mixing Terpenes into Cannabis Distillates

Finfeed Archived May 29, 2020

Cannabis enthusiasts purchase terps and incorporate them into everything from homemade brownies to vape juice. But there’s one industry that’s had surprisingly less of a symbiotic relationship with terpenes than anyone might have expected; namely the cannabis industry.

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Next Investors Archived Mar 24, 2020

Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.

Creso Pharma set to expand human health product line with technological breakthrough

Finfeed Archived Feb 06, 2020

Creso Pharma has achieved a key technological milestone, developing its first water-soluble microgranulated hemp plant granules product as an expansion of its cannaQIX® human health product line.

Page 1 of 6 next >